Abstract
Classical late-infantile neuronal ceroid lipofuscinosis (LINCL) is caused by mutations in tripeptidyl peptidase I (TPP-I), a pepstatin-insensitive lysosomal protease, resulting in neurodegeneration, acute seizures, visual and motor dysfunction. In vitro studies suggest that TPP-I is secreted from cells and subsequently taken up by neighboring cells, similar to other lysosomal enzymes. As such, TPP-I is an attractive candidate for enzyme replacement or gene therapy. In the present studies, we examined the feasibility of gene transfer into mouse brain using recombinant adenovirus (Ad), feline immunodeficiency virus (FIV) and adeno-associated virus (AAV) vectors expressing TPP-I, after single injections into the striatum or cerebellum. A dual TPP-I- and β-galactosidase-expressing adenovirus vector (AdTTP-I/nlsβgal) was used to distinguish transduced (β-galactosidase positive) cells from cells that endocytosed secreted TTP-I. Ten days after striatal injection of AdTTP-I/nlsβgal, β-galactosidase-positive cells were concentrated around the injection site, corpus callosum, ependyma and choroid plexus. In cerebellar injections, β-galactosidase expression was confined to the region of injection and in isolated neurons of the brainstem. Immunohistochemistry for TPP-I expression showed that TPP-I extended beyond areas of β-galactosidase activity. Immunohistochemistry for TTP-I after FIVTTP-I and AAV5TTP-I injections demonstrated TPP-I in neurons of the striatum, hippocampus and Purkinje cells. For all three vectors, TPP-I activity in brain homogenates was 3–7-fold higher than endogenous levels in the injected hemispheres. Our results indicate the feasibility of vector-mediated gene transfer of TPP-I to the CNS as a potential therapy for LINCL.
Similar content being viewed by others
References
Opitz JM . Ceroid-lipofuscinoses. Batten Disease and Allied Disorders. Alan R. Liss, Inc.: New York, 1987,pp 1–307.
Goebel HH, Mole SE, Lake BD . The Neuronal Ceroid Lipofuscinoses (Batten Disease): Biomedical and Health Research. IOS Press: Amsterdam, 1999, p 33.
Sohar I, Sleat DE, Jadot M, Lobel P . Biochemical characterization of a lysosomal protease deficient in classical late infantile neuronal ceroid lipofuscinosis (LINCL) and development of an enzyme-based assay for diagnosis and exclusion of LINCL in human specimens and animal models. J Neurochem 1999; 73: 700–711.
Palmer DN et al. Mitochondrial ATP synthase subunit c storage in the ceroid-lipofuscinoses (Batten disease). Am J Med Genet 1992; 42: 561–567.
Sleat DE et al. Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 1997; 277: 1802–1805.
Vines D, Warburton MJ . Purification and characterisation of a tripeptidyl aminopeptidase I from rat spleen. Biochim Biophys Acta 1998; 1384: 233–242.
Rawlings ND, Barrett AJ . Tripeptidyl-peptidase I is apparently the CLN2 protein absent in classical late-infantile neuro-nal ceroid lipofuscinosis. Biochim Biophys Acta 1999; 1429: 496–500.
Vines DJ, Warburton MJ . Classical late infantile neuronal ceroid lipofuscinosis fibroblasts are deficient in lysosomal tripeptidyl peptidase I. FEBS Lett 1999; 443: 131–135.
Lin L, Sohart I, Lackland H, Lobel P . The human CLN2 protein/tripeptidyl-peptidase I is a serine protease that autoactivates at acIdic pH. J Biol Chem 2001; 276: 2249–2255.
Ezaki J, Takeda-Ezaki M, Kominami E . Tripeptidyl peptidase I, the late infantile neuronal ceroid lipofuscinosis gene product, initiates the lysosomal degradation of subunit c of ATP synthase. J Biochem 2000; 128: 509–516.
Ezaki J, Tanida I, Kanehagi N, Kominami E . A lysosomal proteinase, the late infantile neuronal ceroid lipofuscinosis gene (CLN2) product, is essential for degradation of a hydrophobic protein, the subunit c of ATP synthase. J Neurochem 1999; 72: 2573–2582.
Lin L, Lobel P . Production and characterization of recombinant human CLN2 protein for enzyme-replacement therapy in late infantile neuronal ceroid lipofus. Biochem J 2001; 357: 49–55.
Xia H, Mao Q, Davidson BL . The HIV Tat protein transduction domain improves the biodistribution of β-glucuronidase expressed from recombinant viral vectors. Nat Biotechnol 2001; 19: 640–644.
Consiglio A et al. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat Med 2001; 7: 310–316.
Ghodsi A et al. Extensive β-glucuronidase activity in murine CNS after adenovirus mediated gene transfer to brain. Hum Gene Ther 1998; 9: 2331–2340.
Stein CS, Ghodsi A, Derksen T, Davidson BL . Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. J Virol 1999; 73: 3424–3429.
Vogler C et al. Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease. J Inherit Metab Dis 1998; 21: 575–586.
Bosch A et al. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum Gene Ther 2000; 11: 1139–1150.
Brooks AI et al. Functional correction of established CNS deficits in an animal model of lysosomal storage disease using feline immunodeficiency virus-based vectors. Proc Natl Acad Sci USA 2002; 99: 6216–6221.
Alisky JM et al. Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors. NeuroReport 2000; 11: 2669–2673.
Davidson BL et al. Recombinant AAV type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian CNS. Proc Natl Acad Sci USA 2000; 97: 3428–3432.
Fu H et al. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. Mol Ther 2002; 5: 42–49.
Barranger JA, O'Rourke E . Lessons learned from the development of enzyme therapy for Gaucher disease. J Inherit Metab Dis 2001; 24: 89–96.
Desnick RJ, Banikazemi M, Wasserstein M . Enzyme replacement therapy for Fabry disease, an inherited nephropathy. Clin Nephrol 2002; 57: 1–8.
Leone P, Janson CG, McPhee SJ, During MJ . Global CNS gene transfer for a childhood neurogenetic enzyme deficiency: Canavan disease. Curr Opin Mol Ther 1999; 1: 487–492.
Ghodsi A et al. Systemic hyperosmolality improves β-glucuronidase distribution and pathology in murine MPS VII brain following intraventricular gene transfer. Exp Neurol 1999; 160: 109–116.
Anderson RD et al. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther 2000; 7: 1034–1038.
Chartier C et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol 1996; 70: 4805–4810.
Johnston JC et al. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J Virol 1999; 73: 4991–5000.
Chiorini JA et al. High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors. Hum Gene Ther 1995; 6: 1531–1541.
Davidson BL, Chiorini JA . Recombinant adeno-associated virus vector types 4 and 5: preparation and application for CNS gene transfer. Viral Vectors Gene Ther 2003 (in press).
Page AE, Fuller K, Chambers TJ, Warburton MJ . Purification and characterization of a tripeptidyl peptidase I from human osteoclastomas: evidence for its role in bone resorption. Arch Biochem Biophys 1993; 306: 354–359.
Acknowledgements
The authors thank Dr Istvan Sohar and Dr Peter Lobel for assistance with the TPP-I activity assays, Dr Sybille Sauter for the FIVTPP plasmid, Inês Martins and Ken Ratliff for excellent technical assistance and Drs Colleen Stein and Jason Heth for critical discussions. We also thank the University of Iowa Gene Transfer Vector Core (DK 54759) for help with virus production. This work was supported in part by a grant from the Batten Disease Support and Research Association (BDSRA), and from the Roy J. Carver Trust (BLD).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haskell, R., Hughes, S., Chiorini, J. et al. Viral-mediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-I to the mouse central nervous system. Gene Ther 10, 34–42 (2003). https://doi.org/10.1038/sj.gt.3301843
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301843
- Springer Nature Limited
Keywords
This article is cited by
-
Neuronal Ceroid Lipofuscinosis: Potential for Targeted Therapy
Drugs (2021)
-
Development and functions of the choroid plexus–cerebrospinal fluid system
Nature Reviews Neuroscience (2015)
-
Enhanced Survival of the LINCL Mouse Following CLN2 Gene Transfer Using the rh.10 Rhesus Macaque-derived Adeno-associated Virus Vector
Molecular Therapy (2007)
-
Timing of Therapeutic Intervention Determines Functional and Survival Outcomes in a Mouse Model of Late Infantile Batten Disease
Molecular Therapy (2007)
-
AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL
Gene Therapy (2005)